EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases

Max Charles Herman iD, Maya Marzello, Zoaib Habib Tharwani, Snigdha Kotaru iD, Yoav D Piura, Eric Newman, Gregory S Day iD, Andrew McKeon iD, A Sebastian Lopez-Chiriboga iD, Sarosh R Irani iD

Annals of Clinical and Translational Neurology · 03.11.2026

DOI: 10.1002/acn3.70578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 03.11.2026. Verfasst von Max Charles Herman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome, Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of paraclinical parameters compared in discovery and validation cohorts. CSF GAD65‐antibody titers ≥ 1 nmol/L performed best in discovery (AUC 0.956) and validation (AUC 0.949; p = 0.814), with 89.7% sensitivity and 94% specificity for identifying tGAD65. Serum titers > 20 nmol/L and indices of intrathecal synthesis showed lower discriminative ability. Our finding aims to reduce misdiagnosis and identify potential immunotherapy‐responsive diseases.

Schlagwörter

Stichwörter der Autor:innen

cerebellar ataxiaglutamic acid decarboxylase 65 (GAD65)limbic encephalitisstiff person syndrometemporal lobe epilepsy

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

ORCID-Profile: Max Charles Herman, Snigdha Kotaru, Gregory S Day, Andrew McKeon, A Sebastian Lopez-Chiriboga, Sarosh R Irani

Förderung

  • Wellcome
  • Medical Research Council
  • Wellcome Trust

Zitieren

APA

Herman, M. C., Marzello, M., Tharwani, Z. H., Kotaru, S., Piura, Y. D., Newman, E., Day, G. S., McKeon, A., Lopez-Chiriboga, A. S., & Irani, S. R. (2026). Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70578

Vancouver

Herman MC, Marzello M, Tharwani ZH, Kotaru S, Piura YD, Newman E, et al. Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70578

BibTeX
@article{Herman2026,
  author = {Herman, Max Charles and Marzello, Maya and Tharwani, Zoaib Habib and Kotaru, Snigdha and Piura, Yoav D and Newman, Eric and Day, Gregory S and McKeon, Andrew and Lopez-Chiriboga, A Sebastian and Irani, Sarosh R},
  title = {Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70578}
}
Kostenlos starten →